During the call, please submit questions via the Skype window.

Both audio and visuals are available through the Skype Meeting Broadcast link and are accessible via any browser, either PC or mobile.
Today’s Speakers

Heather Zenk  
Sr. Vice President,  
Replenishment & Secure  
Supply Chain Operations

Keyvan Nekouei  
Sr. Director, Account  
Experience & Clinical  
Services

During the call, please submit questions via the Skype Q&A window.

Both audio and visuals are available through the Skype Meeting Broadcast link and are accessible via any browser, either PC or mobile.
COVID-19 Vaccine Updates

“Some vaccine products, such as those with ultra-cold temperature requirements, will be shipped directly from the manufacturer.”

“Jurisdictions should consider partnering with the private sector... to provide vaccine in closest proximity to the prioritized populations as possible, given the limitations with the product.”

Phase 1a “Jumpstart Phase”: High-risk workers in healthcare facilities; First Responders

Phase 1b: People of all ages with comorbid and underlying conditions that put them at … higher risk; Older adults living in congregate or overcrowded settings.

Retail should not expect to see vaccine until at least January

CDC documents released 8/28
Remdesivir Update

- The Emergency Use Authorization (EUA) for Remdesivir was extended on Friday, August 28, 2020

- About Remdesivir & the EUA
  - Investigational drug that went through National Institutes of Health (NIH) clinical trial
  - FDA issued EUA allowing administration to hospitalized patients with COVID-19
  - EUA allows for distribution and use by licensed health care providers
  - EUA updated/expanded August 28, 2020
  - Candidates for treatment must be hospitalized COVID-19 patients:
    - adults/children
    - with suspected or laboratory confirmed COVID-19
Product & Supply Chain Updates

- **GlaxoSmithKline**
  - While respiratory product inventory position has improved since March, we expect GlaxoSmithKline products **Advair** and **Flovent** will remain on allocation likely until the end of the calendar year to continue to manage constrained inventory
  - Currently, GSK products represent about 23% of the overall branded omits at AmerisourceBergen

- **KALETRA® from AbbVie**
  - Moved from wholesale to specialty distribution ~ 6 months ago to better manage a surge in demand
  - Will be returned to wholesale distribution channel next week (September 12) as AbbVie has successfully rebounded their inventory

- **Remember!** You can always utilize the **Key Shortage Report** and **Drug Shortage Notes**, both of which are available through reporting in ABC Order and ABC Passport
Reminder: Enhanced Aggregated Allocation Functionality

Old Functionality
- The previous functionality allowed customers to identify a group of accounts for which they would like to combine purchasing potential for allocated product(s), rather than setting allocations at the individual customer account level. The functionality was limited to products on Market Shortage allocation.

New Functionality
- Aggregated allocation is now available to combine purchasing potential for both Market Shortage and AmerisourceBergen allocated product.
- Reminder:
  - Market Shortage allocations are typically defined by the manufacturer
  - ABC Allocation items might be placed on allocation proactively by AmerisourceBergen, for example, if we are experiencing higher-than-usual demand, if product availability is erratic, in times of API disruption, etc.

What do you have to do?
- If you are already signed up for aggregated allocation, **no action needs to be taken.** We added the AmerisourceBergen allocation type to your aggregated groups starting August 28.
- If you would like to sign up for aggregated allocation, please reach out to your AmerisourceBergen rep, and they can help you complete the enrollment.
Q & A

Please submit questions directly in the Skype window
We are united in our responsibility to create healthier futures.